Evaluation of Risk Profiles for Gastrointestinal and Cardiovascular Adverse Effects in Nonselective NSAID and COX-2 Inhibitor Users
- 1 January 2008
- journal article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 31 (2), 143-158
- https://doi.org/10.2165/00002018-200831020-00004
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Characterizing new users of NSAIDs before and after rofecoxib withdrawalBritish Journal of Clinical Pharmacology, 2007
- Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX‐2 cardiovascular profilePharmacoepidemiology and Drug Safety, 2006
- The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin ConfoundingThe Journal of Clinical Pharmacology, 2005
- Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic diseaseInternal Medicine Journal, 2004
- Incidence of serious upper gastrointestinal bleeding/perforation in the general population:: Review of epidemiologic studiesJournal of Clinical Epidemiology, 2002
- Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United KingdomPharmacoepidemiology and Drug Safety, 2001
- Selective Prescribing of SpasmolyticsAnnals of Pharmacotherapy, 2000
- North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritisBMJ, 1998
- Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems.Journal of Epidemiology and Community Health, 1992
- A chronic disease score from automated pharmacy dataJournal of Clinical Epidemiology, 1992